验证 SARS-CoV-2 替代病毒中和试验在康复和接种疫苗的医护人员中的效果。
Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers.
机构信息
Virology Department, Hôpital Paul Brousse, INSERM U1193, AP-HP, Université Paris Saclay, 94804 Villejuif, France.
Institute for Physiology and Pathophysiology, Johannes Kepler University Linz, 4040 Linz, Austria.
出版信息
Viruses. 2023 Feb 2;15(2):426. doi: 10.3390/v15020426.
Vaccination against COVID-19 is the main public health approach to fight against the pandemic. The Spike (S) glycoprotein of SARS-CoV-2 is the principal target of the neutralizing humoral response. We evaluated the analytical and clinical performances of a surrogate virus neutralization test (sVNT) compared to conventional neutralization tests (cVNTs) and anti-S eCLIA assays in recovered and/or vaccinated healthcare workers. Our results indicate that sVNTs displayed high specificity and no cross-reactivity. Both eCLIA and sVNT immunoassays were good at identifying cVNT serum dilutions ≥1:16. The optimal thresholds when identifying cVNT titers ≥1:16, were 74.5 U/mL and 49.4 IU/mL for anti-S eCLIA and sVNT, respectively. Our data show that neutralizing antibody titers (Nab) differ from one individual to another and may diminish over time. Specific assays such as sVNTs could offer a reliable complementary tool to routine anti-S serological assays.
接种 COVID-19 疫苗是抗击大流行的主要公共卫生措施。SARS-CoV-2 的 Spike（S）糖蛋白是中和体液免疫反应的主要目标。我们评估了替代病毒中和试验（sVNT）与常规中和试验（cVNTs）和抗 S 酶联免疫吸附试验（eCLIA）在康复和/或接种疫苗的医护人员中的分析和临床性能。我们的结果表明，sVNTs 显示出高特异性和无交叉反应性。eCLIA 和 sVNT 免疫测定都擅长识别 cVNT 血清稀释度≥1:16。当识别 cVNT 滴度≥1:16 时，抗 S eCLIA 和 sVNT 的最佳阈值分别为 74.5 U/mL 和 49.4 IU/mL。我们的数据表明，中和抗体滴度（Nab）因人而异，并且可能随时间推移而降低。特定的检测方法，如 sVNTs，可以为常规抗 S 血清学检测提供可靠的补充工具。
Zotero 插件